Linvoseltamab-gcpt (Lynozyfic) for relapsed/refractory multiple myeloma
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.743 alerts
Get alerted when Policy CP.PHAR.743 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, dosing limits, and coverage criteria for Linvoseltamab-gcpt (Lynozyfic) in adult patients with relapsed or refractory multiple myeloma across commercial, HIM, and Medicaid lines of business.
HCPCS J9601 (linvoseltamab-gcpt) was added and previous temporary codes removed/updated in the coding section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.